All peptides
CJC-1295
Research / Investigational
CJC-1295 is a synthetic analog of GHRH designed to stimulate endogenous growth hormone release, often studied with and without a DAC (drug affinity complex) moiety.
Buy CJC-1295 on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
CJC-1295 is a synthetic analog of GHRH designed to stimulate endogenous growth hormone release, often studied with and without a DAC (drug affinity complex) moiety.
FDA Approval Status
Not approved by the FDA. Investigational or intended for research purposes only.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs to increase pulsatile growth hormone secretion.
Current Research
Phase I/II data on GH release and IGF-1 elevation exist; no approved clinical indication.
Research strength: Moderate
Potential Medical Uses
- Investigational only
Potential Benefits
- Elevated GH/IGF-1 in studies
- Studied for potential lean mass and recovery effects
Known Side Effects
- Injection-site reactions
- Flushing
- Headache
- Water retention
Contraindications
- Active malignancy
- Pregnancy
- Uncontrolled diabetes
Drug Interactions
- May potentiate insulin sensitivity changes
- Interacts with somatostatin analogs
Administration Methods
- Subcutaneous injection
Half-life
~8 days with DAC; ~30 min without DAC
Reconstitution
Bacteriostatic water; typical 2 mg vial reconstituted with 1–2 mL.
Storage & Handling
Lyophilized: freeze or refrigerate. Reconstituted: 2–8 °C, use within 2–4 weeks.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.